Indications
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of eosinophilic esophagitis (EoE) in paediatric patients 2 to 17 years of age.
Composition
- Active substance
- Budesonide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jorveza
- Active substance
- Budesonide
- ATC code
- A07EA06
- Therapeutic area
- Esophageal Diseases
- Marketing authorisation holder
- Dr. Falk Pharma GmbH
- Status